UCL HUNTINGTON’S DISEASE RESEARCH
We’re thrilled to announce that the results of the TRACK-HD study have just been published in the high-impact scientific journal The Lancet Neurology.
TRACK-HD was a multi-site international study that aimed to establish what measurements were the best to use as ‘outcome measures’ for clinical trials in HD. It was funded by the CHDI Foundation and led by Prof Sarah Tabrizi at UCL.
The Lancet Neurology article – the third TRACK-HD publication in the journal in three years – proposes a ‘toolkit’ of outcome measurements, including optimised MRI brain scan measures and cognitive (thinking) tests that will help to make clinical trials more efficient and more effective.
Many drugs are in development for HD and a major problem has been a lack of ‘biomarkers’ to help us decide whether a drug works or not. TRACK-HD has successfully identified biomarkers that we hope will achieve that aim, bringing us closer to clinical trials and effective treatments for HD.
Though TRACK-HD has now completed, we’re in the process of setting up a follow-on study, TrackOn-HD, which aims to identify measurements sensitive enough to detect change reliably in people with the HD genetic mutation before they develop symptoms. Stay tuned for more news as TrackOn-HD nears launch.